Compare Amphastar Pharmaceuticals Inc (AMPH) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Williams-Sonoma, Inc. trades at $250.52 (market cap $29.53B). The key difference: Williams-Sonoma, Inc. is far larger — about 34.2× Amphastar Pharmaceuticals Inc's market cap, and Williams-Sonoma, Inc. pays a 1.21% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | WSM | |
|---|---|---|
Market Cap | $863.95M | $29.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $251.81 |
52-Week Low | $16.87 | $168.64 |
Enterprise Value | $1.26B | $30.38B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Williams-Sonoma (WSM) trades at $251.81, up 1.94% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Fundamentally, the company maintains robust profitability with a 13.81% net income margin and has beaten earnings estimates for three consecutive quarters. A dividend of $0.76 is scheduled for payment in August 2026, reflecting shareholder returns.
WSM's outlook is supported by consistent earnings outperformance and high profitability metrics like 54.01% ROE. However, valuation multiples such as a P/E of 28.23 appear elevated relative to historical norms. Key risks include consumer discretionary spending volatility and competitive pressures in home furnishings. Analyst consensus is mixed with a $222.22 price target below the current price, suggesting cautious optimism amid rich valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
